Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma.

Goodstein, Taylor; Yang, Yuanquan; Runcie, Karie; Srinivasan, Ramaprasad; Singer, Eric A

Goodstein, Taylor; Yang, Yuanquan; Runcie, Karie; Srinivasan, Ramaprasad; Singer, Eric A.

Afiliação

Goodstein T; Division of Urologic Oncology.
Yang Y; Divsion of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Runcie K; Division of Medical Oncology, Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York.
Srinivasan R; Molecular Therapeutics Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Singer EA; Division of Urologic Oncology.

Curr Opin Oncol ; 35(3): 206-217, 2023 05 01.

Article em En | MEDLINE | ID: mdl-37226958

Assuntos

Carcinoma de Células Renais; Neoplasias Renais; Humanos; Carcinoma de Células Renais/tratamento farmacológico; Estudos Retrospectivos; Neoplasias Renais/tratamento farmacológico; Fatores de Transcrição Hélice-Alça-Hélice Básicos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Curr Opin Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google